Additional Advances in Multiple Myeloma Research and Clinical Trials With Rahul Banerjee, MD, FACP

Oncology Data Advisor

Dr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health’s online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for patients with multiple myeloma. Click the links below for the full activity! Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma Live or Virtual Meeting Series: https://www.i3health.com/live/hemonc-fellows-lecture-series-leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma